GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » EV-to-Revenue

Egetis Therapeutics AB (OSTO:EGTX) EV-to-Revenue : 34.54 (As of Dec. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Egetis Therapeutics AB's enterprise value is kr2,348.68 Mil. Egetis Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was kr68.00 Mil. Therefore, Egetis Therapeutics AB's EV-to-Revenue for today is 34.54.

The historical rank and industry rank for Egetis Therapeutics AB's EV-to-Revenue or its related term are showing as below:

OSTO:EGTX' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.37   Med: 22.65   Max: 4095.82
Current: 34.55

During the past 13 years, the highest EV-to-Revenue of Egetis Therapeutics AB was 4095.82. The lowest was -0.37. And the median was 22.65.

OSTO:EGTX's EV-to-Revenue is ranked worse than
74.38% of 1042 companies
in the Biotechnology industry
Industry Median: 7.635 vs OSTO:EGTX: 34.55

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-13), Egetis Therapeutics AB's stock price is kr6.59. Egetis Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.23. Therefore, Egetis Therapeutics AB's PS Ratio for today is 28.53.


Egetis Therapeutics AB EV-to-Revenue Historical Data

The historical data trend for Egetis Therapeutics AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB EV-to-Revenue Chart

Egetis Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.88 23.36 25.27 62.16 25.04

Egetis Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.04 25.04 28.98 18.12 22.01

Competitive Comparison of Egetis Therapeutics AB's EV-to-Revenue

For the Biotechnology subindustry, Egetis Therapeutics AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's EV-to-Revenue falls into.



Egetis Therapeutics AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Egetis Therapeutics AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2348.679/68
=34.54

Egetis Therapeutics AB's current Enterprise Value is kr2,348.68 Mil.
Egetis Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr68.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egetis Therapeutics AB  (OSTO:EGTX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Egetis Therapeutics AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.59/0.231
=28.53

Egetis Therapeutics AB's share price for today is kr6.59.
Egetis Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egetis Therapeutics AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines